Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the precise function of IL-17A in inflammatory bowel disease (IBD) remains controversial.
|
31755523 |
2020 |
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The increased expression of IL-17 was observed in both intestinal compartments of IBD patients when compared to controls.
|
31563276 |
2020 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Retinoic Acid Related Orphan Nuclear Receptor gamma T (RORγT) is a lineage specifying transcription factor for IL-17 expressing cells, which may contribute to the pathogenesis of Inflammatory Bowel Disease (IBD).
|
31549280 |
2020 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Experimental evidence "proves" that IL-17 plays a critical role in the pathogenesis of inflammatory bowel disease, but blocking IL-17 makes Crohn's disease worse.
|
31736274 |
2020 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
After 1 year of follow-up, the odds of having IBD were 2.85 (<i>p</i> = .0213) and 1.42 (<i>p</i> = .1891) times higher in the anti-IL-17a and PDE4i cohorts, respectively, compared to the biologic-naïve cohort, and 2.86 (<i>p</i> = .0253) and 1.21 (<i>p</i> = .4978) times higher compared to the non-IBD-indicated biologic cohort.
|
31106607 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TAK-828F strongly inhibited IL-17 gene expression with IC<sub>50</sub> values from 21.4 to 34.4 nmol/L in PBMCs from anti-TNF mAb naive and treatment-failure patients of IBD.
|
30972425 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical trials showed the effectiveness of IL23/IL-17 axis inhibition in both spondyloarthritis (SpA) and Inflammatory Bowel Disease (IBD).
|
31197599 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-17-producing Th17 cells and IFN-γ and IL-17 double-producing Th1/17 cells have been identified as the pathogenic cells in inflammatory bowel disease (IBD).
|
30121880 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Serious adverse effects occur less frequently and specific to the psoriasis treatment option, such as inflammatory bowel disease and candida infections with IL-17 inhibitors, tuberculosis with certolizumab pegol, and psychiatric events with apremilast.
|
31046481 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Up to December 2018, eight cases of new-onset inflammatory bowel disease (IBD) were reported in the literature in patients being treated with secukinumab, an interleukin-17A antagonist prescribed for dermatologic or rheumatologic indications.
|
31168691 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, intestinal NIK signaling is active in mouse models of colitis and patients with inflammatory bowel diseases; meanwhile, constitutive NIK signaling increases the susceptibility to inflammatory injury by inducing ectopic M-cell differentiation and a chronic increase of IL-17A.
|
30737385 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Contrastingly, enterotoxigenic Bacteroides fragilis (ETBF) is highly associated with inflammatory bowel disease (IBD) and colorectal cancer (CRC), rapidly inducing IL-17-dependent murine colitis and tumorigenesis.
|
30279518 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
E. coli isolates from IBD patients had various virulence genes and were associated with increased expression of TNF-α and IL-17.
|
31034508 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, it is lack of depth in whether TGP regulate T helper 17 cell (Th17) / T regulatory cell (Treg) immune balance or interleukin 23 (IL-23) / IL-17 axis to achieve the goal of treating IBD.
|
30612460 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Spondyloarthritis (SpA), a chronic inflammatory, rheumatic disease, and hidradenitis suppurativa (HS), a chronic, debilitating, inflammatory skin disease, share several clinical and pathophysiological features, such as the association with inflammatory bowel disease and elevated cytokine levels IL-17 and TNF-α.
|
29751976 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with non-inflamed tissues, both total mast cells and IL-17A-positive mast cells were increased in psoriatic skin dermis and in submucosa from inflammatory bowel disease gut.
|
30517745 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This is the first case report of de-novo severe Crohn's-like IBD in association with the use of Ixekizumab requiring rescue with escalated dosing of anti-TNF therapy and highlights the importance of close monitoring in patients being treated with IL-17 inhibitors, especially in those patients with known risk factors for inflammatory bowel disease.
|
31488067 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
ILC3 contribute to the progression and aggravation of IBD while both IL-22 and IL-17, along with IFN-γ, are overexpressed by the dysregulation of NCR<sup>-</sup> ILC3 or NCR<sup>+</sup> ILC3 function and the bias of NCR<sup>+</sup> ILC3 towards ILC1 as well as regulatory ILC dysfunction in the pathological state.
|
30962426 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of interleukin-17A (IL-17A) was evident in children with UC compared to both non-IBD and CD patients.
|
31261370 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, however, IL-17 blockade remains ineffective or even pathogenic against important autoimmune diseases such as inflammatory bowel disease (IBD).
|
30765202 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of IL-17 immunity is well established in patients with inflammatory diseases, such as psoriasis and inflammatory bowel disease, but not in asthmatic patients, in whom further study is required.
|
30998987 |
2019 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To characterize the relationship between IL-17 inhibition and inflammatory bowel disease.
|
28521565 |
2018 |
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-23-mediated Th-17 cell activation and stimulation of IL-17-driven pro-inflammatory axis has been associated with autoimmunity disorders such as Inflammatory Bowel Disease (IBD) or Crohn’s Disease (CD).
|
29966384 |
2018 |
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL17A and IL17F expression levels were significantly increased in inflamed IBD mucosa.
|
30193869 |
2018 |
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-17A mRNA was significantly reduced in IBS and CRC but unchanged in IBD.
|
30186819 |
2018 |